GLAND Gland Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Gland Pharma reported a strong Q4 and full year FY26, marked by 22% YoY revenue growth and a 500 bps EBITDA margin expansion in Q4. This performance was fueled by new product launches, robust CDMO segment growth, and the successful turnaround of Cenexi. The company remains confident in its growth trajectory, supported by a strong pipeline and ongoing capacity investments, despite some regional market challenges and potential raw material price increases.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 22.5%, net profit up 44.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,063 | 1,011 | 1,030 | 1,039 | 1,074 +1% | 1,178 +17% | 1,262 +23% |
| EBITDA | 364 | 391 | 394 | 359 | 375 +3% | 422 +8% | 508 +29% |
| Net profit | 282 | 295 | 290 | 269 | 302 +7% | 308 +4% | 420 +45% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
